论文部分内容阅读
诱发角膜新生血管的因素涉及各种生长因子。研究表明:在角膜新生血管中广泛存在的血管内皮生长因子(vascular endothelial growth factor,VEGF)起着主要作用。一种可行的治疗角膜新生血管策略是:通过特异性的中和抗VEGF抗体竞争性的结合VEGF,从而抑制VEGF活性。近年来,利用抗VEGF治疗策略,抑制脉络膜新生血管获得了很好的效果。靶向VEGF治疗药物的疗效和安全性已经证明。因此我们设想,局部应用新的抗VEGF药物,如贝伐单抗、兰尼单抗等可以有效地抑制角膜新生血管,恢复角膜透明和视力。
Factors that induce corneal neovascularization involve various growth factors. Studies have shown that vascular endothelial growth factor (VEGF), which is widespread in corneal neovascularization, plays a major role. A viable approach to treating corneal neovascularization is to inhibit VEGF activity by competitively binding VEGF with specific neutralizing anti-VEGF antibodies. In recent years, the use of anti-VEGF treatment strategy, inhibition of choroidal neovascularization obtained good results. The efficacy and safety of targeted VEGF therapies have proven. Therefore, we hypothesized that the topical application of new anti-VEGF drugs such as bevacizumab and ranibizumab may effectively inhibit corneal neovascularization and restore corneal transparency and visual acuity.